0000000000056214

AUTHOR

Juan José Gómez-doblas

showing 4 related works from this author

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) <65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct

Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH…

2018

During the last few years, the number of patients receiving anticoagulant and antiplatelet therapy has increased worldwide. Since this is a chronic treatment, patients receiving it can be expected to need some kind of surgery or intervention during their lifetime that may require treatment discontinuation. The decision to withdraw antithrombotic therapy depends on the patient's thrombotic risk versus hemorrhagic risk. Assessment of both factors will show the precise management of anticoagulant and antiplatelet therapy in these scenarios. The aim of this consensus document, coordinated by the Cardiovascular Thrombosis Working Group of the Spanish Society of Cardiology, and endorsed by most o…

Malemedicine.medical_specialtymedicine.drug_classHemorrhage030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsThromboembolismIntervention (counseling)Preoperative CareAntithromboticmedicineHumans030212 general & internal medicineIntensive care medicineAgedAged 80 and overThrombotic riskIntraoperative CareDrug Substitutionbusiness.industryAnticoagulantAnticoagulantsGeneral MedicinePerioperativemedicine.diseaseThrombosisDiscontinuationConventional PCIFemaleAntiagregación Anticoagulación Anticoagulation Antiplatelet Antithrombotic Antitrombótico Cirugía SurgerybusinessPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19.

2020

Abstract Background the coronavirus disease 2019 (COVID-19) is characterized by poor outcomes and mortality, particularly in older patients. Methods post hoc analysis of the international, multicentre, ‘real-world’ HOPE COVID-19 registry. All patients aged ≥65 years hospitalised for COVID-19 were selected. Epidemiological, clinical, analytical and outcome data were obtained. A comparative study between two age subgroups, 65–74 and ≥75 years, was performed. The primary endpoint was all cause in-hospital mortality. Results about, 1,520 patients aged ≥65 years (60.3% male, median age of 76 [IQR 71–83] years) were included. Comorbidities such as hypertension (69.2%), dyslipidaemia (48.6%), card…

MaleAgingmedicine.medical_specialtyInternational CooperationPopulation030204 cardiovascular system & hematologycomorbiditiesRisk Assessment03 medical and health sciencesAcademicSubjects/MED002800302 clinical medicineRisk FactorsInternal medicineEpidemiologymedicineClinical endpointDementiaHumans030212 general & internal medicineHospital MortalityRegistriesMortalityeducationGeriatric Assessmentolder adultsAgedAged 80 and overeducation.field_of_studyCoronavirus disease 2019business.industrySARS-CoV-2COVID-19MultimorbidityGeneral Medicinemedicine.diseasePrognosisComorbidityHospitalizationAgeingIntensive Care UnitsRespiratory failureHeart failureFemaleGeriatrics and GerontologybusinessDyslipidemiaResearch PaperAge and ageing
researchProduct

Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-leve…

2019

Background The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation [OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each age stratum, precise cost-effectiveness and sensitivity simulations can be performed based on the age distribution of the population/region to be screened. Such calculations are required by national authorities and organisations responsible for health system budgets to determine the best age cutoffs for screening programs and d…

MaleHealth ScreeningEconomicsSocial Sciences030204 cardiovascular system & hematologyVascular MedicineScreening programmeElectrocardiography0302 clinical medicineRisk FactorsHealth careAtrial FibrillationMedicine and Health SciencesMass ScreeningPublic and Occupational Health030212 general & internal medicinemedia_commonAged 80 and overRAge FactorsGeneral MedicineMiddle AgedUniversity hospitalPrognosis3. Good healthStrokeBioassays and Physiological AnalysisNeurologyHealthMedicineFemaleTraining programArrhythmiaResearch ArticleAdultCerebrovascular DiseasesCost-Effectiveness AnalysisCardiologyLibrary scienceResearch and Analysis MethodsRisk AssessmentStroke risk03 medical and health sciencesYoung AdultAge DistributionSex FactorsPopulation MetricsPredictive Value of TestsPolitical sciencemedia_common.cataloged_instanceHumansEarly careerEuropean unionIschemic StrokeAgedHealth Care PolicyPopulation Biologybusiness.industryElectrophysiological TechniquesBiology and Life SciencesNumber needed to screenEconomic AnalysisHealth CareAge GroupsPeople and PlaceseHealthPopulation GroupingsCardiac ElectrophysiologybusinessScreening Guidelines
researchProduct